Open-Label Extension Study to Pioneer Study 6058-SCD-101

This is an open-label study to evaluate the safety and tolerability of long-term treatment with pociredir without a comparator in participants with SCD who have previously been treated and shown benefit with pociredir in feeder study 6058-SCD-101 (NCT05169580). Participants in this study will receive once daily doses of pociredir for up to 48 months.

NCT Number	NCT07401823
Lead Sponsor	Fulcrum Therapeutics
Conditions	Sickle Cell Disease
Enrollment	50 participants
Start Date	2026-03-30
Primary Completion	2030-02-04 (estimated)
Study Completion	2030-07-05 (estimated)
Updated on ClinicalTrials.gov	2026-04-14